First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.

Area of Science:

• Gastroenterology
• Immunology
• Clinical Trials

Background:

• Several biologics exist for ulcerative colitis (UC), but identifying optimal first-line treatments is crucial.
• This study evaluated the superiority of infliximab (IFX) compared to vedolizumab (VED) and ustekinumab (UST) in biologic-naïve UC patients.

Purpose of the Study:

• To assess the efficacy and safety of IFX, VED, and UST as first-line biologic therapies for moderate-to-severe ulcerative colitis.
• To compare clinical remission rates at week 12 and treatment continuation rates at week 26 among the three biologics.

Main Methods:

• A multicenter, randomized controlled trial involving 107 biologic-naïve UC patients across 20 Japanese institutions.
• Patients were randomly assigned to receive IFX, VED, or UST.
• Primary endpoint was clinical remission at week 12; secondary endpoints included treatment continuation at week 26 and adverse events.

Main Results:

• Clinical remission rates at week 12 were 36.4% (IFX), 32.4% (VED), and 43.3% (UST).
• Treatment continuation rates at week 26 were 50.0% (IFX), 58.3% (VED), and 82.4% (UST).
• Adverse events were reported in 14.7% (IFX), 16.7% (VED), and 5.9% (UST). Thiopurine use with IFX and lower baseline disease activity with VED were associated with remission.

Conclusions:

• The study's small sample size limits definitive conclusions on primary endpoints.
• Preliminary findings suggest potential benefits of thiopurine co-administration with IFX and early disease control with VED.
• Further research with larger cohorts is needed to establish first-line biologic superiority in UC.